Last reviewed · How we verify

Intranasal challenge drug

New York State Psychiatric Institute · Phase 3 active Small molecule

Intranasal challenge drug is a Small molecule drug developed by New York State Psychiatric Institute. It is currently in Phase 3 development for Psychiatric research and challenge testing (Phase 3 investigational use).

An intranasal challenge agent used to provoke or test physiological responses in psychiatric research settings.

An intranasal challenge agent used to provoke or test physiological responses in psychiatric research settings. Used for Psychiatric research and challenge testing (Phase 3 investigational use).

At a glance

Generic nameIntranasal challenge drug
SponsorNew York State Psychiatric Institute
ModalitySmall molecule
Therapeutic areaPsychiatry
PhasePhase 3

Mechanism of action

Intranasal challenge drugs are administered via nasal inhalation to induce acute neurobiological or behavioral responses in controlled research environments. These agents are typically used in Phase 3 psychiatric studies to model disease states, test treatment efficacy, or investigate underlying pathophysiology. The specific mechanism depends on the active agent, which is not identified in the available information.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intranasal challenge drug

What is Intranasal challenge drug?

Intranasal challenge drug is a Small molecule drug developed by New York State Psychiatric Institute, indicated for Psychiatric research and challenge testing (Phase 3 investigational use).

How does Intranasal challenge drug work?

An intranasal challenge agent used to provoke or test physiological responses in psychiatric research settings.

What is Intranasal challenge drug used for?

Intranasal challenge drug is indicated for Psychiatric research and challenge testing (Phase 3 investigational use).

Who makes Intranasal challenge drug?

Intranasal challenge drug is developed by New York State Psychiatric Institute (see full New York State Psychiatric Institute pipeline at /company/new-york-state-psychiatric-institute).

What development phase is Intranasal challenge drug in?

Intranasal challenge drug is in Phase 3.

What are the side effects of Intranasal challenge drug?

Common side effects of Intranasal challenge drug include Nasal irritation, Transient anxiety or distress, Headache.

Related